Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Elanco Animal Health announced a new restructuring plan focused on expanding profit margins, reshaping its global footprint, and funding more innovation. The plan includes a global headcount reduction of approximately 300 employees, along with about 300 additional roles that will be replaced by positions in growth areas or lower-cost geographies.
The company expects pretax charges of about $175 million, with roughly $130 million in cash-based costs, most to be paid over the next two years, and around $45 million in non-cash asset impairment charges. These impairments are mainly tied to closing its Kansas City, Missouri implant facility and exiting part of its Monheim, Germany facility.
In connection with its 2025 Investor Day, Elanco issued a press release reaffirming its fourth quarter and full-year 2025 guidance and discussing its innovation and financial outlook, as well as the restructuring actions.
Elanco Animal Health Inc. reported an insider equity transaction by its President, CEO and Director, Jeffrey N. Simmons. On 11/28/2025, Simmons acquired 119.0047 deferred stock units tied to Elanco common stock at a reference price of $23.27 per unit.
After this transaction, Simmons beneficially owned 18,474.9261 deferred stock units, held directly. Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent.
The units are part of the company’s Executive Deferral and Stock Match Plan and will settle in cash or shares after Simmons’ termination of employment or in a specified future year, according to the plan’s terms.
Elanco Animal Health executive Rajeev A. Modi reported an automatic award of deferred stock units tied to company stock. On 11/28/2025, he acquired 60.7916 deferred stock units at a reference price of $23.27. After this transaction, he beneficially owns 7,291.0368 derivative securities in the form of deferred stock units held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of common stock after Modi’s employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan. Modi serves as Executive Vice President U.S. Pet Health and Global Digital Transformation, and this filing reflects his ongoing equity-based compensation.
Elanco Animal Health Inc. director Kapila K. Anand reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, Anand acquired 10,314 shares of Elanco common stock at a stated price of $0, reflecting a board compensation grant rather than a market purchase. After this grant, Anand beneficially owned 94,973 shares of Elanco common stock in direct ownership. The filing notes that this grant is part of the standard annual equity award program for non-employee members of the company’s Board of Directors.
Elanco Animal Health Inc. director reports equity grant. A non-employee member of Elanco’s Board of Directors reported receiving a grant of 10,314 shares of common stock on 11/28/2025 as an annual equity award, structured as deferred stock units with a stated price of $0 for reporting purposes. Following this award, the director beneficially owns 12,853 shares of Elanco common stock in direct ownership. The transaction was reported on a Form 4 as a routine board compensation grant.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. reported receiving an annual equity award on 11/28/2025. The filing shows an award of 10,314 shares of common stock, recorded at a price of $0 as a grant of deferred stock units to a non-employee member of the Board of Directors. Following this grant, the director beneficially owns 88,714 shares of Elanco common stock in direct ownership. This is a routine Form 4 disclosure of director compensation in equity rather than a cash transaction.
Elanco Animal Health Inc. reported an equity award to one of its directors. On 11/28/2025, director Kirk P. McDonald received a grant of 10,314 shares of common stock in the form of deferred stock units as an annual equity award for non-employee board members, at a stated price of $0 per share.
Following this award, McDonald beneficially owns 88,714 shares of Elanco common stock in direct ownership. The filing reflects standard board compensation and does not describe any cash transaction for the company.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the reporting person acquired 10,314 shares of common stock at a stated price of $0, reflecting a board compensation grant rather than an open‑market purchase. Following this award, the director beneficially owned 121,773 shares of Elanco common stock in direct ownership. The grant is described as an annual equity award to each non‑employee member of the company’s board of directors.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. (ELAN) reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a stated price of $0, reflecting a board compensation grant rather than an open-market purchase. Following this transaction, the director beneficially owns 89,714 shares of Elanco common stock held directly.
The filing notes that this award is part of the regular annual equity compensation provided to non‑employee members of Elanco’s Board of Directors, aligning director pay with shareholder interests through stock-based compensation.
Elanco Animal Health Inc. director R. David Hoover reported an equity grant tied to his board service. On 11/28/2025, he received 10,314 shares of common stock as an annual equity award in the form of deferred stock units at a stated price of $0, reflecting a non-cash grant for a non-employee director. After this grant, he beneficially owns 106,773 shares of Elanco common stock directly and an additional 210,000 shares through a Revocable Trust and 15,920 shares through the Suzanne A. Hoover Revocable Trust. The filing is made as a Form 4 by a single reporting person in his capacity as a director.